Home / Precision Medicine (page 10)

Precision Medicine

Two Biomarkers Appear to Predict Course of Idiopathic Pulmonary Fibrosis

ATS 2017, WASHINGTON, DC — Two T cell biomarkers appear to predict the survival trajectory of patients with idiopathic pulmonary fibrosis (IPF), a lung disease that has a varied, but ultimately devastating, impact on patients, according to new research presented at the ATS 2017 International Conference. T-cells marshal the body’s …

Read More »

Targeted Therapy Can Delay Recurrence of Intermediate-Stage Lung Cancer

ASCO Perspective “This study identifies a subset of patients with lung cancer who can benefit from a targeted treatment that causes far fewer side effects than chemotherapy,” said ASCO President-Elect Bruce E. Johnson, MD, FASCO. “It’s also clear evidence that we can use precision medicine not only in patients with …

Read More »

Alexion and Rady Children’s Institute for Genomic Medicine Partner to Speed Diagnosis of Rare Genetic Disorders in Newborns

SAN DIEGO & NEW HAVEN, Conn.–(BUSINESS WIRE)–The Rady Children’s Institute for Genomic Medicine (RCIGM) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced a strategic partnership to accelerate the diagnosis of critically-ill newborns with rare genetic disorders. The collaboration combines the Institute’s genomic research expertise with Alexion data science and bioinformatics capabilities …

Read More »

GenomeDx and Color Partner to Advance Precision Medicine for Prostate Cancer Patients

SAN DIEGO and BURLINGAME, Calif., May 12, 2017 /PRNewswire/ — GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced a collaboration with Color to offer its Color Test, a hereditary cancer risk genetic test that analyzes 30 genes. The collaboration further expands GenomeDx’s broad product offering …

Read More »

Roche to Present New Data on Personalized Medicines and Cancer Immunotherapies at the ASCO Annual Meeting

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data on 20 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from 2 June to 6 June in Chicago, United States. More than 190 abstracts have been accepted, including two “late breakers” …

Read More »

New Research Suggests Current Genetic Testing Guidelines May Miss Breast Cancer Patients who Could Benefit from Testing

LAS VEGAS, April 28, 2017 /PRNewswire/ — New research suggests that current clinical guidelines on the use of genetic testing in breast cancer patients are too narrow and allow patients with pathogenic variants to be missed. The findings were presented at the American Society of Breast Surgeons (ASBS) Annual Meeting …

Read More »

Tracking Unstable Chromosomes Helps Predict Lung Cancer’s Return

Scientists have found that unstable chromosomes within lung tumors increases the risk of cancer returning after surgery, and have used this new knowledge to detect relapse long before standard testing. These are the first findings from the Cancer Research UK-funded TRACERx* lung cancer study, published today (Wednesday) in the New …

Read More »

H3 Biomedicine Extends Collaboration with Foundation Medicine to Develop Precision Therapies for Cancer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, today announced that is has extended its multi-year collaboration with Foundation Medicine, Inc. for the discovery and development of precision …

Read More »

Illumina Advances the Use of Genomics in Precision Oncology, Donates Thousands of Somatic Interpretations to CIViC

umin SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced it is contributing more than 8,000 associations of somatic genetic alterations—variants linked to tumors—to the Clinical Interpretation of Variants in Cancer (CIViC) resource, an openly accessible database hosted by Washington University in St. Louis that can be used in precision medicine. …

Read More »

Bristol-Myers to Leverage Foundation Medicine’s Platform to Identify Predictive Biomarkers

NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Foundation Medicine (NASDAQ:FMI) today announced a collaboration that leverages Foundation Medicine’s comprehensive genomic profiling and molecular information solutions to identify predictive biomarkers such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in patients enrolled across clinical trials investigating Bristol-Myers …

Read More »